Ran Xu1, Maggie Xing1, Kavon Javaherian1, Robert Peters1, Will Ross1, Carlos Bernal-Mizrachi2,3. 1. Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA. 2. Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St. Louis, Missouri, USA. 3. Division of Endocrinology, St. Louis VA Medical Service, St. Louis, Missouri, USA.
Abstract
Background: We conducted a randomized controlled trial of EpxDiabetes, a novel digital health intervention as an adjunct therapy to reduce HbA1c and fasting blood glucose (FBG) among patients with type 2 diabetes mellitus (T2DM). In addition, we examined the effect of social determinants of health on our system. Methods: Sixty-five (n = 65) patients were randomized at a primary care clinic. Self-reported FBG data were collected by EpxDiabetes automated phone calls or text messages. Only intervention group responses were shared with providers, facilitating follow-up and bidirectional communication. ΔHbA1c and ΔFBG were analyzed after 6 months. Results: There was an absolute HbA1c reduction of 0.69% in the intervention group (95% confidence interval [CI], -1.41 to 0.02) and an absolute reduction of 0.03% in the control group (95% CI, -0.88 to 0.82). For those with baseline HbA1c >8%, HbA1c decreased significantly by 1.17% in the intervention group (95% CI, -1.90 to -0.44), and decreased by 0.02% in the control group (95% CI, -0.99 to 0.94). FBG decreased in the intervention group by 21.6 mg/dL (95% CI, -37.56 to -5.639), and increased 13.0 mg/dL in the control group (95% CI, -47.67 to 73.69). Engagement (proportion responding to ≥25% of texts or calls over 4 weeks) was 58% for the intervention group (95% CI, 0.373-0.627) and 48% for the control group (95% CI, 0.296-0.621). Smoking, number of comorbidities, and response rate were significant predictors of ΔHbA1c. Conclusions: EpxDiabetes helps to reduce HbA1c in patients with uncontrolled T2DM and fosters patient-provider communication; it has definite merit as an adjunct therapy in diabetes management. Future work will focus on improving the acceptability of the system and implementation on a larger scale trial.
Background: We conducted a randomized controlled trial of EpxDiabetes, a novel digital health intervention as an adjunct therapy to reduce HbA1c and fasting blood glucose (FBG) among patients with type 2 diabetes mellitus (T2DM). In addition, we examined the effect of social determinants of health on our system. Methods: Sixty-five (n = 65) patients were randomized at a primary care clinic. Self-reported FBG data were collected by EpxDiabetes automated phone calls or text messages. Only intervention group responses were shared with providers, facilitating follow-up and bidirectional communication. ΔHbA1c and ΔFBG were analyzed after 6 months. Results: There was an absolute HbA1c reduction of 0.69% in the intervention group (95% confidence interval [CI], -1.41 to 0.02) and an absolute reduction of 0.03% in the control group (95% CI, -0.88 to 0.82). For those with baseline HbA1c >8%, HbA1c decreased significantly by 1.17% in the intervention group (95% CI, -1.90 to -0.44), and decreased by 0.02% in the control group (95% CI, -0.99 to 0.94). FBG decreased in the intervention group by 21.6 mg/dL (95% CI, -37.56 to -5.639), and increased 13.0 mg/dL in the control group (95% CI, -47.67 to 73.69). Engagement (proportion responding to ≥25% of texts or calls over 4 weeks) was 58% for the intervention group (95% CI, 0.373-0.627) and 48% for the control group (95% CI, 0.296-0.621). Smoking, number of comorbidities, and response rate were significant predictors of ΔHbA1c. Conclusions: EpxDiabetes helps to reduce HbA1c in patients with uncontrolled T2DM and fosters patient-provider communication; it has definite merit as an adjunct therapy in diabetes management. Future work will focus on improving the acceptability of the system and implementation on a larger scale trial.
Entities:
Keywords:
diabetes; digital health; e-health; glycemic control; self-monitoring; telemedicine
Authors: Walter Palmas; Jeanne Teresi; Philip Morin; L Thomas Wolff; Lesley Field; Joseph P Eimicke; Linnea Capps; Alejandro Prigollini; Irma Orbe; Ruth S Weinstock; Steven Shea Journal: Telemed J E Health Date: 2006-10 Impact factor: 3.536
Authors: Mohammed K Ali; Kai McKeever Bullard; Jinan B Saaddine; Catherine C Cowie; Giuseppina Imperatore; Edward W Gregg Journal: N Engl J Med Date: 2013-04-25 Impact factor: 91.245
Authors: Airin C R Simon; Frits Holleman; Wouter T Gude; Joost B L Hoekstra; Linda W Peute; Monique W M Jaspers; Niels Peek Journal: Artif Intell Med Date: 2013-06-02 Impact factor: 5.326
Authors: Anne Holbrook; Lehana Thabane; Karim Keshavjee; Lisa Dolovich; Bob Bernstein; David Chan; Sue Troyan; Gary Foster; Hertzel Gerstein Journal: CMAJ Date: 2009-07-07 Impact factor: 8.262
Authors: Anqi Zhang; Jinsong Wang; Xiaojuan Wan; Ziyi Zhang; Shuhan Zhao; Zihe Guo; Chufan Wang Journal: Int J Environ Res Public Health Date: 2022-03-31 Impact factor: 3.390